SAN DIEGO, Aug. 22, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) will present additional detailed pre-clinical pharmacology and pharmacokinetic data on ralinepag (APD811), the Company's next-generation, oral, selective prostacyclin receptor (IP) agonist intended for the treatment of pulmonary arterial hypertension (PAH), on August 29 at the European Society of Cardiology Congress (ESC) 2017. ESC is taking place August 26 – 30 at the Fira Gran Via in Barcelona, Spain.
The presentations will comprise ralinepag IP receptor binding affinity, selectivity and comparative functional potency versus approved IP agonists. Biological responses highlighting the pharmacology and pharmacokinetics of ralinepag in rat PAH models, human platelets, human pulmonary arteries and human pulmonary artery smooth muscle cells from PAH patients will be presented.
"The pre-clinical pharmacology data continue to support our belief that ralinepag is a potential best-in-class oral prostacyclin therapy," said Amit D. Munshi, President and Chief Executive Officer of Arena. "The acceptance of the scientific data presentation at ESC is representative of the enthusiasm of clinical investigators and scientists to continue exploring the novel profile of ralinepag."
Presentation Details Title: Comparative receptor pharmacology, preclinical efficacy and pharmacokinetics of a novel, next-generation prostacyclin receptor agonist, ralinepag (APD811), in humans and rats Session: Progress in the management of pulmonary hypertension Date/Time: Tuesday, August 29, 11:18 a.m. CET Rapid Fire Abstract: 5019 Location: Agora 1 – Agora
Title: APD811 (ralinepag), a novel non-prostanoid IP receptor agonist, has potent antiproliferative and vasorelaxant properties in human pulmonary artery Session: Progress in the management of pulmonary hypertension Date/Time: Tuesday, August 29, 11:36 a.m. CET Rapid Fire Abstract: 5021 Location: Agora 1 – Agora
About Arena Pharmaceuticals Arena Pharmaceuticals is a biopharmaceutical company focused on developing novel, small molecule drugs with optimized receptor pharmacology designed to deliver broad clinical utility across multiple therapeutic areas. Our proprietary pipeline includes potentially first- or best-in-class programs for which we own global commercial rights. Our three most advanced investigational clinical programs are ralinepag (APD811) which has completed a Phase 2 trial for pulmonary arterial hypertension (PAH), etrasimod (APD334) in Phase 2 evaluation for multiple autoimmune indications, and APD371 in Phase 2 evaluation for the treatment of pain associated with Crohn's disease. In addition, Arena has collaborations with the following pharmaceutical companies: Eisai Co., Ltd. and Eisai Inc. (commercial stage), Axovant Sciences (Phase 2 candidate), and Boehringer Ingelheim International GmbH (preclinical candidate).
Forward-Looking Statements Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. These statements may be identified by introductory words such as "intended," "will," "belief," "potential," "designed" or words of similar meaning, or by the fact that they do not relate strictly to historical or current facts. Such forward-looking statements include statements about the upcoming presentations, the potential of ralinepag, advancement of our pipeline, our focus, and the potential of our programs and collaborations. For such statements, we claim the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from our expectations. Factors that could cause actual results to differ materially from the forward-looking statements include: the timing and outcome of research, development and regulatory review is uncertain; enrolling patients in our ongoing and intended clinical trials is competitive and challenging; we expect to need additional funds to advance all of our programs, and you and others may not agree with the manner we allocate our resources; our drug candidates may not advance in development or be approved for marketing; risks related to developing and commercializing drugs; the risk that Arena's revenues are based in part on estimates, judgment and accounting policies, and incorrect estimates or disagreement regarding estimates or accounting policies may result in changes to Arena's guidance or previously reported results; government and third-party payor actions, including relating to reimbursement and pricing; risks related to relying on collaborative arrangements; the entry into or modification or termination of collaborative arrangements; unexpected or unfavorable new data; nonclinical and clinical data are voluminous and detailed, and regulatory agencies may interpret or weigh the importance of data differently and reach different conclusions than Arena or others, request additional information, have additional recommendations or change their guidance or requirements before or after approval; topline data may not accurately reflect the complete results of a particular study or trial; Arena's and third parties' intellectual property rights; results of clinical trials and other studies are subject to different interpretations and may not be predictive of future results; clinical trials and other studies may not proceed at the time or in the manner expected or at all; satisfactory resolution of litigation or other disagreements with others; and those factors disclosed in our filings with the Securities and Exchange Commission, including our Form 10-Q for the quarter ended June 30, 2017. These forward-looking statements represent our judgment as the time of this release. We disclaim any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.
Corporate Contact: Kevin R. Lind Arena Pharmaceuticals, Inc. Executive Vice President and Chief Financial Officer [email protected] 858.210.3636
Media Contact: Matt Middleman, M.D. LifeSci Public Relations [email protected] 646.627.8384